Las Fuentes North Health Center, Aragon Health Service, 50002 Zaragoza, Spain.
Aragonese Primary Care Research Group (GAIAP), Aragon Health Research Institute (IISA), 50009 Saragossa, Spain.
Int J Environ Res Public Health. 2022 May 31;19(11):6746. doi: 10.3390/ijerph19116746.
(1) Background: Evaluation and improvement of the management of patients with atrial fibrillation in treatment with oral anticoagulants from primary health care. (2) Methods: prospective quasi-experimental study, conducted on 385 patients assisted with Atrial Fibrillation (AF) at the Las Fuentes Norte Health Center, before and after the implementation of actions to improve oral anticoagulants management from October 2015 to July 2017. (3) Results: The ACO-ZAR I study revealed that the population with AF presents a global prevalence of 1.7%, an indication of oral anticoagulants of 92.1%, undertreatment of 24%, suboptimal control of vitamin K antagonists of 43%, use of antiaggregant as primary prevention of 13.42%, and primary health care monitoring of 34%. The implementation of activities aimed at improving the management of oral anticoagulants in the ACO-ZAR II study achieves a reduction in undertreatment up to 16%, in the use of antiaggregant up to 9%, and in suboptimal control up to 30%, as well as an increase in control from primary health care up to 69.2% and of the penetrance of direct oral anticoagulants up to 28%. (4) Conclusions: In conclusion, the application of activities aimed at optimizing the management of oral anticoagulants in health center patients allowed the improvement of risk assessment and registration, undertreatment, use of antiaggregant, suboptimal control of vitamin K antagonists, control by primary health care center, and the penetrance of direct oral anticoagulants.
(1) 背景:评估和改善初级保健中口服抗凝剂治疗心房颤动患者的管理。(2) 方法:前瞻性准实验研究,在 2015 年 10 月至 2017 年 7 月实施改善口服抗凝剂管理的措施之前和之后,对 Las Fuentes Norte 健康中心的 385 名心房颤动 (AF) 患者进行了干预。(3) 结果:ACO-ZAR I 研究表明,AF 人群的全球患病率为 1.7%,口服抗凝剂的指示率为 92.1%,治疗不足率为 24%,维生素 K 拮抗剂的控制不佳率为 43%,抗血小板药物作为一级预防的使用率为 13.42%,初级保健监测率为 34%。在 ACO-ZAR II 研究中实施的旨在改善口服抗凝剂管理的活动可将治疗不足率降低至 16%,将抗血小板药物使用率降低至 9%,将控制不佳率降低至 30%,将初级保健控制率提高至 69.2%,将直接口服抗凝剂的渗透率提高至 28%。(4) 结论:总之,在健康中心患者中应用旨在优化口服抗凝剂管理的活动可改善风险评估和登记、治疗不足、抗血小板药物的使用、维生素 K 拮抗剂的控制不佳、初级保健中心的控制以及直接口服抗凝剂的渗透率。